PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
41.00%
Gross profit growth above 1.5x AXSM's 25.15%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
27.93%
Positive EBIT growth while AXSM is negative. John Neff might see a substantial edge in operational management.
27.93%
Positive operating income growth while AXSM is negative. John Neff might view this as a competitive edge in operations.
29.77%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
30.61%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
30.61%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.13%
Share count expansion well above AXSM's 0.45%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.13%
Diluted share count expanding well above AXSM's 0.45%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
32.67%
OCF growth at 75-90% of AXSM's 43.30%. Bill Ackman would demand better working capital management or cost discipline.
32.86%
FCF growth 75-90% of AXSM's 43.68%. Bill Ackman might push for improved capital allocation or operational changes to match the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.05%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
75.83%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
20.41%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
95.17%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
79.59%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
2.82%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
170.99%
Below 50% of AXSM's 1702.38%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-42.91%
Negative 5Y equity/share growth while AXSM is at 212.08%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-60.55%
Negative 3Y equity/share growth while AXSM is at 154.06%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while AXSM invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-18.27%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.43%
We’re deleveraging while AXSM stands at 0.43%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-31.86%
Our R&D shrinks while AXSM invests at 7.08%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-15.50%
We cut SG&A while AXSM invests at 4.35%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.